Reported Monday August 25, 2025: NLS Pharmaceutics Postpones Shareholders' Meeting On Kadimastem Merger To September 16 To Address SEC Feedback And Provide Updated Information

Author: Benzinga Newsdesk | August 26, 2025 11:52am

On August 21, 2025, the board of directors of NLS Pharmaceutics Ltd. (the "Company") rescheduled the meeting date of the Extraordinary Shareholders' Meeting to approve the transactions relating to its contemplated transaction with Kadimastem Ltd. ("Kadimastem"), which was originally scheduled to take place on August 25, 2025, or the Meeting. This postponement is intended to allow additional time for the Company to receive and evaluate further comments from the U.S. Securities and Exchange Commission ("SEC") on the Company's pending registration statement on Form F-4 relating to the proposed merger transaction with Kadimastem, and to ensure that shareholders have access to the most current and complete information in considering the matters to be presented at the Meeting. The Meeting has been currently rescheduled to occur on September 16, 2025, but may be postponed to a later date, if necessary.

Posted In: NLSP